ClinicalTrials.gg
CompletedNCT00439686Updated Oct 5, 2026

Study of ZIO-201 in Advanced Sarcoma

A Phase 1/2 interventional study of ZIO-201 in Advanced Sarcoma, sponsored by Alaunos Therapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Alaunos Therapeutics · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2006, registered Feb 2007).
Updated Oct 5, 2026Interventions changedEnrollment updated+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The study of safety of Isophosphoramide Mustard (IPM) in the treatment of advanced sarcoma.

02

Conditions studied

  • Advanced Sarcoma
03

In context

Lead sponsor

Alaunos Therapeutics is the lead sponsor of 37 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

and /or unresectable disease state after previous standard chemotherapy

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Phase 1: Palifosfamide-lysine 590 mg/m²

    Participants received palifosfamide-lysine 590 mg/m² by intravenous infusion over approximately 15 minutes on Days 1, 2, and 3 of each 21-day cycle. Four participants were treated at this dose level. Dose escalation was discontinued after 2 of 4 participants experienced dose-limiting toxicities during Cycle 1.

    Drug: ZIO-201

  • Experimental
    Phase 2: Palifosfamide-lysine 413 mg/m²

    Participants received palifosfamide-lysine 413 mg/m² by intravenous infusion over approximately 15 minutes on Days 1, 2, and 3 of each 21-day cycle. Forty-nine participants were treated at this dose level. The last 6 participants enrolled also participated in a pharmacokinetic substudy in which they received a single dose of palifosfamide-tris 178 mg/m² on Day -14 before beginning palifosfamide-lysine treatment.

    Drug: ZIO-201

Interventions

  • DrugIsophosphamide mustardStudies of Isophosphamide mustardIsophosphamide mustard pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Palifosfamide-lysine (ZIO-201) was administered by intravenous infusion on Days 1, 2, and 3 of each 21-day cycle. Dose and formulation are specified in the corresponding Arm descriptions.

    Also known as: palifosfamide

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1

    DLTs were assessed during the first 21-day cycle to determine the maximum tolerated dose (MTD). A DLT was defined as any of the following: a non-hematologic Grade 3 toxicity that did not resolve to Grade 2 or lower within 72 hours, excluding alopecia any non-hematologic Grade 4 toxicity, excluding alopecia Grade 4 granulocyte and/or platelet toxicity lasting 7 days or longer Grade 3 or higher neutropenia with an unexplained temperature of 38.5°C or higher on 2 or more occasions within 24 hours The MTD was the dose level below the dose at which at least 33% of participants had a DLT.

    Time frame: Cycle 1 (21 days)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of Palifosfamide

    Cmax of palifosfamide, measured from blood samples collected during Cycle 1 dosing.

    Time frame: Cycle 1, Days 1 to 3

  2. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Palifosfamide

    AUC0-inf of palifosfamide, measured from blood samples collected during Cycle 1 dosing.

    Time frame: Cycle 1, Days 1 to 3

07

Study locations

2 sites
  • Santa Monica, California, United States
  • Ann Arbor, Michigan, United States
08

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Feb 2006 to primary completion in Jan 2008, 22 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Jun 2008 → Jan 2008 and completion Dec 2013 → Jan 2008.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2007
First posted
Feb 26, 2007
StartActual
Feb 21, 2006
Primary completionActual
Jan 16, 2008was Jun 2008
CompletionActual
Jan 16, 2008was Dec 2013
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2008→Jan 16, 2008
Sep 30, 2026
Study completion
Dec 2013→Jan 16, 2008
Sep 30, 2026
Enrollment
53→54
Oct 1, 2026
Interventions
Arm changed Arm 1: Experimental: Phase 1, palifosfamide 590 mg/m².→Phase 1: Palifosfamide-lysine 590 mg/m²; Phase 2, palifosfamide 413 mg/m².→Phase 2: Palifosfamide-lysine 413 mg/m². Arms added: Arm 1: Experimental: Phase 1, palifosfamide 590 mg/m².·Phase 2, palifosfamide 413 mg/m².; arms removed: Single Arm
across 2 updates, Oct 1, 2026 – Oct 5, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore toxicitiesNow Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1Time frame: 6 months → Cycle 1 (21 days)
Oct 1, 2026
Secondary outcomes
2 added, 1 removed
What changed in the outcomes
  • AddedMaximum Plasma Concentration (Cmax) of PalifosfamideTime frame: Cycle 1, Days 1 to 3
  • AddedArea Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of PalifosfamideTime frame: Cycle 1, Days 1 to 3
  • RemovedpharmacokineticsTime frame: 6 months
Oct 1, 2026
Show all 3 updates
  1. Oct 5, 2026
    Interventions Arm changed Arm 1: Experimental: Phase 1, palifosfamide 590 mg/m².→Phase 1: Palifosfamide-lysine 590 mg/m²; Phase 2, palifosfamide 413 mg/m².→Phase 2: Palifosfamide-lysine 413 mg/m²
    + 2 other changes: verification date and design details
  2. Oct 1, 2026
    Enrollment 53→54
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore toxicitiesNow Number of Participants With Dose-Limiting Toxicities (DLTs) in Cycle 1Time frame: 6 months → Cycle 1 (21 days)
    Secondary outcomes 2 added, 1 removed
    What changed in the outcomes
    • AddedMaximum Plasma Concentration (Cmax) of PalifosfamideTime frame: Cycle 1, Days 1 to 3
    • AddedArea Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of PalifosfamideTime frame: Cycle 1, Days 1 to 3
    • RemovedpharmacokineticsTime frame: 6 months
    Interventions Arms added: Arm 1: Experimental: Phase 1, palifosfamide 590 mg/m².·Phase 2, palifosfamide 413 mg/m².; arms removed: Single Arm
    + 2 other changes: design details and index terms
  3. Sep 30, 2026
    Primary completion Jun 2008→Jan 16, 2008
    Study completion Dec 2013→Jan 16, 2008
    + 4 other changes: identifiers, verification date, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT00439686
Responsible party
Sponsor
First posted
Feb 26, 2007
Start date
Feb 21, 2006
Primary completion
Jan 16, 2008
Completion
Jan 16, 2008
Last update
Oct 5, 2026

Study contacts

Jonathan Lewis, MD, PhD
study director · ZIOPHARM Oncology, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Isophosphamide mustard

Start the discussion